Ken Griffin Avidity Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 43,100 shares of RNA stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,100
Previous 63,400
32.02%
Holding current value
$1.32 Million
Previous $1.84 Million
30.98%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$350 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$347 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$297 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$283 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$268 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.6B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...